Ratings and dated fundamentals
Exact eligible report scores in ranking order. Ratings summarize dated reports, not future returns; report and market dates remain in the table.
See the complete ratings and dated fundamentals
Scroll sideways to compare all columns. Select a heading to sort.
| 1 | ZOETIS INC. | ZTS | 4 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $79.4 | $32,261,502,071.8 | 12.98 | 9.77 |
| 2 | Elanco Animal Health Incorporated Common Stock | ELAN | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $25.74 | $12,865,548,704.58 | Not reported | 1.94 |
| 3 | Immucell Corp | ICCC | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $9.8 | $89,005,530.6 | 113.04 | 2.84 |
| 4 | Petco Health and Wellness Company, Inc. Class A Common Stock | WOOF | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.96 | $959,662,008.48 | 31.7 | 0.8 |
| 5 | Zhengye Biotechnology Holding Limited Class A Ordinary Shares | ZYBT | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $1.5 | $71,087,064 | Not reported | 1.62 |
| 6 | Neogen Corp | NEOG | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $11.76 | $2,567,278,959.84 | Not reported | 1.23 |
| 7 | PetMed Express, Inc. | PETS | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.22 | $26,448,275.08 | Not reported | 1.15 |
No matching rows. Clear the filter to see all records.
7 companies with eligible ratings and dated fundamentals, from 7 eligible companies in this selection.
Inspect a rated peer
Ratings and dated fundamentals
Phibro Animal Health Corporation Class A (PAHC): source evidence dated 2026-11-07T12:42:51.530Z.
- Rank
- 1
- Company
- ZOETIS INC.
- Ticker
- ZTS
- Rating / 5
- 4
- Report date
- 2025-12-31
- Fiscal period
- 2025 FY
- Model
- anthropic/claude-haiku-5-5
- Market day
- 2026-11-06
The selected ticker, rating, report date and producing model match the first displayed row. Equal ratings use ticker order.
Which recorded peer has the highest usable rating?
The provider's peer set defines membership. It does not establish identical risk or business models. Read report dates and producing models.
NexusTrade stock ratings and report filters- Median market capitalization
- $959,662,008.48 · 7 / 7 displayed companies
- Median positive P/E (TTM)
- 31.7 · 3 / 7 displayed companies
- Median positive price / book
- 1.62 · 7 / 7 displayed companies
- Largest company by market cap
- ZOETIS INC. (ZTS) · $32,261,502,071.8
- Largest company's share of displayed market cap
- 66.05% · Sum of displayed market caps; not portfolio weights or revenue exposure
Check each median’s included count and each company’s market date. These are unweighted summaries of displayed companies, not a sector index or revenue exposure.
Research PAHC
Open a peer's company view and compare how it actually earns revenue with the anchor company.
Research PAHCKeep reporting dates and units beside the answer, and inspect its original citations.
How these companies are related
Peer membership comes from the same related-company provider used by NexusTrade's stock research. The provider identifies related companies using news coverage and returns data. A related company can be a competitor or a thematic peer; this list does not imply identical products or financial exposure.
Peer membership was fetched 2026-10-12.
The rating determines the order after peer membership is selected. The anchor company is excluded. Companies without an eligible report rating or dated fundamentals are counted in coverage and left out of the ranked table.
What best means in this list
This list was refreshed on 2026-11-07 using existing company reports. The report date in each row is the date of the underlying analysis; refreshing the list does not create a new company report.
Best means the highest stored NexusTrade report ratings within this selection. Ratings use the product's 1-to-5 scale. The list sorts by rating from high to low, with ticker order breaking equal-rating ties. A rating summarizes a report; it does not predict a stock's return.
The peer set comes from the recorded related-company provider. Similarity defines which companies enter this comparison; it does not establish that they have equal business models, risk or expected returns.
What the leading companies do
The first 5 companies below lead the ratings in this snapshot; equal ratings are ordered by ticker. Their company profiles describe different businesses even when they share the Phibro Animal Health Corporation Class A (PAHC) selection.
These are company descriptions, not estimates of revenue from this theme. Industry membership does not identify a pure-play business or establish how much sales depend on it. Open the company profile and examine segment disclosures before treating an overlapping classification as equivalent exposure.
ZOETIS INC. (ZTS): 4 / 5
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Elanco Animal Health Incorporated Common Stock (ELAN): 3 / 5
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Immucell Corp (ICCC): 2.5 / 5
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Petco Health and Wellness Company, Inc. Class A Common Stock (WOOF): 2.5 / 5
Petco Health and Wellness Company, Inc., operates as a health and wellness company, focuses on enhancing the lives of pets, pet parents, and its Petco partners in the United States, Mexico, and Puerto Rico. The company provides veterinary care, grooming, training, tele-health, and Vital Care and pet health insurance services, as well as veterinary services through Vetco mobile clinics. It also offers pet consumables, supplies, and services through its petco.com, petcoach.co, petinsurancequotes.com, and pupbox.com websites. The company offers its products under the WholeHearted, Reddy, and Well & Good brands. Petco Health and Wellness Company, Inc. was founded in 1965 and is headquartered in San Diego, California.
Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT): 2.5 / 5
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Valuation and company size within this selection
These summaries use the 7 displayed companies. Each company retains its own market observation date in the ratings table above. Medians are unweighted; they are not a sector index valuation.
Positive P/E and price-to-book values are summarized separately. Missing, zero and negative values are excluded from those medians, with the included count shown. A lower multiple alone does not establish better value: profitability, growth, debt and business mix can differ.
Show the table · 5 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Median market capitalization | $959,662,008.48 | 7 / 7 displayed companies |
| Median positive P/E (TTM) | 31.7 | 3 / 7 displayed companies |
| Median positive price / book | 1.62 | 7 / 7 displayed companies |
| Largest company by market cap | ZOETIS INC. (ZTS) | $32,261,502,071.8 |
| Largest company's share of displayed market cap | 66.05% | Sum of displayed market caps; not portfolio weights or revenue exposure |
No matching rows. Clear the filter to see all records.
Other business classifications in the list
A company can appear in several product and revenue classifications. These overlapping memberships help identify different business mixes to investigate; they are not verified revenue shares or mutually exclusive subindustries.
Show the table · 5 rows, 2 columns
| Additional classification | Matching displayed companies |
|---|---|
| Veterinary | 7 / 7 |
| Pharmaceuticals | 6 / 7 |
| Biotechnology | 5 / 7 |
| Manufacturing | 5 / 7 |
| Healthcare | 4 / 7 |
No matching rows. Clear the filter to see all records.
Dates and coverage
Report dates range from 2025-12-31 to 2025-12-31. Market observations range from 2026-11-06 to 2026-11-06. These dates may differ across companies. Daily closes are not synchronized live quotes.
The selection includes 0 companies without a report, 0 with invalid latest rating metadata, 0 with older reports, 0 with missing required fundamentals and 0 with out-of-date market observations. Missing companies receive no substitute score.
How the ranking is built
The ranking uses the latest stored report at or before the refresh cutoff for each active eligible company. The report date, fiscal year/period and producing model remain visible. The latest invalid score is excluded; an older favorable score does not replace it. Publication policy stock-ratings-v1 accepts report ages up to 550 days and market observations up to 10 calendar days, with a positive close and market capitalization. Optional missing ratios remain not reported.
Report ages can differ substantially, particularly between annual and quarterly reports. Different producing models may also use different judgments. Read the date, fiscal period and model before comparing scores. Private report analysis and account data are not published here.
A refresh reads existing reports and market data. It does not rerun a model or create a new analysis. Compare business fundamentals and your own research constraints alongside the score before making a decision.